Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.
Well, I agree but don’t want to be accused of ramping! Lol! I also think it very likely.
If we really are turning the corner here in terms of SO sells, and it’s a big if of course, but IF we are, it would be a good idea for shorts to consider closing and bids to be put in by big pharma, if that’s potentially on the cards anytime soon. Does have a different feeling today I think. This could shoot up in the blink of an eye.
Looking positive today. Timeline fits with SO being potentially out now. Let’s see : )
Yes, salary rise and reward of options is a little unpalatable given the SP drop for long term investors. Many of whom have been incredibly loyal and supportive of DDDD. Hopefully they will receive their reward in the very near future.
These jammy barstewards with fresh ISA money able to buy in at 40p still. Who would have thought!
Very possible it was a buy. Likely was, but surely we would at least see a temporary spike if so, despite background selling?
If it’s SO sell then great, good to be rid. If it’s institutional buys then great too. Look forward to the TR1.
I really do think this will pick up tomorrow. New tax year/Isa etc. great place to park money for the next year at current price. Almost certainly a growth share and potentially monumental re-rate over that time. Maybe #AZN or #Merck are waiting until tomorrow before bidding ; )
£100k buy : )
They have shown with high levels of certainty that the product is safe. They have shown that it increases the efficacy of a world leading multibillion dollar cancer treatment drug. They have multiple products in the pipeline across a range of diseases which are likely to have the same safety profile and potential of success. You had better believe that Merck, Pfizer and others will be interested. This is no one hit wonder company and is already collaborating with the biggest in the business. I’m convinced of a buy out at some stage. It could be very soon.
Or Oxford finance support, or Upfront payments from Merck or another big pharma, or other US II’s. Lots of options for finance when you are proving the science is effective. Which they are. They won’t raise at 40p when shares for directors range from 50p-110p. A Director buy or confirmation of Oxford finance extension (likely in my view) and this will rocket.
Bought a second tranche This gift keeps on giving : )
Bought more : ) cheers!
Nope, going back up again. Stop stressing over a few percent here or there. It means nothing. Big picture here is 4D will be HUGE!
Every day that ticks by is a day closer to SO exit and a day more for II’s to complete their due dilligence and consider a buy in. As soon as market cap increases this will be on the radar of funds that can’t buy in at the present MC. If Merck hasn’t jumped in by then they will have missed the boat or have to buy much higher. There is only one way this is going long term and it’s not down.
Lol! When SO is out, any day now, it will be WAY north of 55p! Just buy and hold : )
Oh good god!
Lol! CRl123 you have absolutely no idea what my job is. I won’t be explaining it to you but suffice it to say I work with plenty of youngsters too. 1000’s in fact. Not putting them down, my comments are solely directed at MB, he/she needs to grow up.
When you learn to speak like an adult @masterblast then I may perhaps listen to you (though probably won’t). Strong suspicion you are living at your mums still.
Wouldn’t want to be out over the weekend…… : )
Golden tickets. An amazing company and amazing results, at bargain basement prices.